{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-018765","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.766377+00:00","generated_at":"2026-06-13T15:28:33.363979+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen reports FY 2023 net loss $59.2M; positive fasedienol, itruvone clinical updates","bullets":["Net loss of $59.2M for FY ended March 31, 2023, vs $48.7M prior year; cash $16.6M.","Positive FDA feedback supports LSAS as primary endpoint for fasedienol Phase 3 FEARLESS program in SAD.","Successful U.S. Phase 1 study of itruvone (PH10) enables Phase 2B development in MDD; Fast Track granted.","PH80 nasal spray showed statistically significant reduction in hot flashes vs placebo in Phase 2A (p<.001).","Company pursuing global partnerships to advance six CNS product candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-018765","json":"https://secwatch.observer/filing/0001437749-23-018765.json","markdown":"https://secwatch.observer/filing/0001437749-23-018765.md","text":"https://secwatch.observer/filing/0001437749-23-018765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/0001437749-23-018765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/vtgn20230628_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:28:33.363979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d2bd212e9f2898ba8ef9153344c8a1c3908c2a1","claim":"Vistagen Therapeutics, Inc. reported financial results for fiscal year ended March 31, 2023.","evidence_excerpt":"today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/0001437749-23-018765-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}